Table 1.
Baseline characteristics of the Japanese patients
| Characteristics | Lenvatinib | Sorafenib |
|---|---|---|
| (N = 81) | (N = 87) | |
| Age (years) | ||
| < 65 | 18 (22) | 30 (34) |
| 65–75 | 42 (52) | 31 (36) |
| ≥ 75 | 21 (26) | 26 (30) |
| Sex | ||
| Male | 65 (80) | 72 (83) |
| Female | 16 (20) | 15 (17) |
| Body weight (kg) | ||
| < 60 | 41 (51) | 46 (53) |
| ≥ 60 | 40 (49) | 41 (47) |
| ECOG PS | ||
| 0 | 76 (94) | 75 (86) |
| 1 | 5 (6) | 12 (14) |
| MPVI | ||
| Yes | 15 (19) | 15 (17) |
| No | 66 (82) | 72 (83) |
| EHS | ||
| Yes | 41 (51) | 45 (52) |
| No | 40 (49) | 42 (48) |
| MPVI, EHS, or both | ||
| Yes | 49 (60) | 52 (60) |
| No | 32 (40) | 35 (40) |
| Child–Pugh class | ||
| A | 81 (100) | 87 (100) |
| C-P score 5 | 58 (72) | 67 (77) |
| C-P score 6 | 23 (28) | 20 (23) |
| B | 0 (0) | 0 (0) |
| BCLC stage | ||
| B | 31 (38) | 34 (39) |
| C | 50 (62) | 53 (61) |
| Etiology of chronic liver disease | ||
| Hepatitis B | 23 (28) | 19 (22) |
| Hepatitis C | 37 (46) | 49 (56) |
| Alcohol | 10 (12) | 6 (7) |
| Other | 5 (6) | 2 (2) |
| Unknown | 6 (7) | 11 (13) |
| Baseline total AFP (ng/mL) | ||
| < 200 | 50 (62) | 59 (68) |
| ≥ 200 | 31 (38) | 28 (32) |
| Median baseline AFP (ng/mL) | 57.1 | 49.8 |
Numbers are presented as n (%) unless otherwise indicated
ECOG PS Eastern Cooperative Oncology Group Performance Status, MPVI macroscopic portal vein invasion, EHS extrahepatic spread, BCLC stage Barcelona Clinic Liver Cancer stage, AFP alpha-fetoprotein